Index RUT P/E - EPS (ttm) -0.25 Insider Own 52.98% Shs Outstand 773.28M Perf Week 2.44%
Market Cap 878.21M Forward P/E - EPS next Y -0.26 Insider Trans 3.16% Shs Float 327.73M Perf Month 17.76%
Income -188.89M PEG - EPS next Q -0.10 Inst Own 27.40% Short Float 23.81% Perf Quarter 27.97%
Sales 863.49M P/S 1.02 EPS this Y -46.29% Inst Trans -3.05% Short Ratio 8.61 Perf Half Y -0.79%
Book/sh 1.80 P/B 0.70 EPS next Y 29.96% ROA -9.04% Short Interest 78.03M Perf Year -9.35%
Cash/sh 0.14 P/C 9.16 EPS next 5Y 12.00% ROE -12.80% 52W Range 0.85 - 2.24 Perf YTD -16.56%
Dividend Est. - P/FCF - EPS past 5Y 1.56% ROI -11.29% 52W High -43.75% Beta 1.81
Dividend TTM - Quick Ratio 1.22 Sales past 5Y 3.29% Gross Margin 26.88% 52W Low 47.96% ATR (14) 0.06
Dividend Ex-Date - Current Ratio 1.55 EPS Y/Y TTM 44.76% Oper. Margin -18.31% RSI (14) 58.31 Volatility 3.78% 5.89%
Employees 3930 Debt/Eq 0.24 Sales Y/Y TTM -14.02% Profit Margin -21.87% Recom 1.00 Target Price 4.25
Option/Short Yes / Yes LT Debt/Eq 0.20 EPS Q/Q 22.10% Payout - Rel Volume 0.21 Prev Close 1.22
Sales Surprise 2.46% EPS Surprise 10.00% Sales Q/Q -1.89% Earnings Feb 27 AMC Avg Volume 9.06M Price 1.26
SMA20 -1.43% SMA50 15.45% SMA200 -9.56% Trades
Volume 1,946,474 Change 3.28%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-29-23 Upgrade Barrington Research
Mkt Perform → Outperform
$2
Dec-15-22 Initiated H.C. Wainwright
Buy
$3
Jan-24-22 Downgrade Barrington Research
Outperform → Mkt Perform
Jun-21-21 Initiated Ladenburg Thalmann
Buy
$7
Nov-25-19 Initiated Piper Jaffray
Overweight
$2.50
Mar-02-18 Downgrade JP Morgan
Neutral → Underweight
Sep-14-17 Downgrade JP Morgan
Overweight → Neutral
Jun-21-16 Reiterated Standpoint Research
Buy
$16 → $18
Jun-03-16 Initiated Standpoint Research
Buy
$16
Mar-31-16 Reiterated Barrington Research
Outperform
$17 → $16
Oct-16-15 Initiated JP Morgan
Overweight
$14
Sep-11-15 Downgrade Jefferies
Buy → Hold
Mar-03-15 Downgrade Oppenheimer
Outperform → Perform
May-12-14 Reiterated Oppenheimer
Outperform
$13 → $12
Mar-14-14 Initiated Oppenheimer
Outperform
$13
Nov-13-13 Reiterated Ladenburg Thalmann
Buy
$10 → $14.50
May-30-13 Reiterated Ladenburg Thalmann
Buy
$8.50 → $10
Oct-22-12 Initiated Barrington Research
Outperform
$6
Dec-01-11 Reiterated Ladenburg Thalmann
Buy
$6 → $8.50
Jul-14-11 Initiated Ladenburg Thalmann
Buy
$6
Show Previous Ratings
Apr-01-24 01:01PM
Mar-28-24 11:08PM
08:00AM
Mar-25-24 09:57AM
Mar-20-24 08:00AM
08:52AM
Loading…
Mar-05-24 08:52AM
Feb-29-24 08:31AM
Feb-28-24 09:31AM
09:02AM
06:18AM
(Thomson Reuters StreetEvents)
Feb-27-24 09:00PM
07:30PM
06:10PM
05:08PM
(Associated Press Finance)
04:43PM
04:05PM
Loading…
04:05PM
Feb-26-24 09:16AM
Feb-22-24 04:05PM
Feb-08-24 01:48PM
Feb-05-24 08:09AM
Jan-22-24 11:48AM
Jan-09-24 04:05PM
Jan-08-24 08:00AM
Jan-04-24 11:31PM
Jan-03-24 05:05PM
Dec-07-23 10:20AM
Dec-06-23 11:30AM
Nov-28-23 07:00AM
Nov-07-23 10:36AM
(Thomson Reuters StreetEvents)
10:29AM
09:19AM
Loading…
09:19AM
06:45AM
01:00AM
Nov-06-23 07:30PM
05:30PM
(Associated Press Finance)
05:01PM
04:05PM
Nov-02-23 10:00AM
Oct-31-23 08:00AM
Oct-25-23 04:25PM
Oct-12-23 10:50AM
Oct-06-23 12:03PM
Sep-29-23 01:03PM
Sep-28-23 07:36PM
04:08PM
Sep-13-23 01:18PM
Sep-12-23 08:30AM
Aug-28-23 11:56AM
Aug-07-23 01:21PM
Aug-04-23 01:00AM
Aug-03-23 05:55PM
04:48PM
04:05PM
Jul-25-23 04:05PM
Jul-23-23 08:11AM
Jul-12-23 08:25AM
Jun-29-23 03:51PM
11:23AM
09:53AM
08:10AM
Jun-28-23 07:03AM
06:51AM
06:45AM
Jun-08-23 07:11AM
Jun-02-23 11:31AM
May-10-23 06:13AM
May-04-23 12:23PM
05:48AM
(Thomson Reuters StreetEvents)
May-03-23 10:00PM
06:25PM
05:23PM
04:05PM
Apr-25-23 04:05PM
Apr-13-23 07:46AM
Mar-17-23 06:21AM
Mar-14-23 12:08PM
Mar-09-23 03:42PM
08:00AM
Mar-08-23 04:34PM
12:01PM
08:05AM
08:01AM
08:00AM
Feb-26-23 07:13AM
06:40AM
Feb-24-23 10:43AM
07:11AM
(Thomson Reuters StreetEvents)
01:00AM
Feb-23-23 04:05PM
Feb-16-23 12:17PM
11:41AM
Feb-13-23 06:03AM
Feb-09-23 07:05AM
Jan-14-23 07:26AM
Jan-03-23 08:00AM
Dec-28-22 10:06AM
Nov-29-22 10:47AM
Nov-16-22 05:08AM
Nov-09-22 08:39AM
Nov-08-22 08:30PM
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
FROST PHILLIP MD ET AL CEO & Chairman Mar 18 '24 Buy 0.87 500,000 437,100 210,968,225 Mar 18 04:45 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 14 '24 Buy 0.89 500,000 444,300 210,468,225 Mar 14 05:00 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 13 '24 Buy 0.93 500,000 463,750 209,968,225 Mar 13 04:44 PM FROST PHILLIP MD ET AL CEO & Chairman Mar 12 '24 Buy 0.93 600,000 559,380 209,468,225 Mar 12 05:27 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 28 '24 Buy 0.99 500,000 496,150 208,868,225 Feb 28 05:31 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 21 '24 Buy 0.99 1,000,000 991,700 208,368,225 Feb 21 05:10 PM FROST PHILLIP MD ET AL CEO & Chairman Feb 07 '24 Buy 0.98 1,500,000 1,462,800 207,368,225 Feb 07 05:09 PM KRASNO RICHARD M Director Jan 29 '24 Buy 0.99 30,000 29,838 103,333 Jan 29 03:30 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 19 '24 Buy 0.98 500,000 488,650 205,868,225 Jan 19 04:54 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 18 '24 Buy 0.97 400,000 386,200 205,368,225 Jan 18 05:06 PM HSIAO JANE PH D Vice Chairman & CTO Jan 17 '24 Buy 0.95 150,000 142,500 27,999,880 Jan 17 05:09 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 16 '24 Buy 0.95 1,000,000 954,300 204,968,225 Jan 16 05:03 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 11 '24 Buy 0.94 511,531 480,379 203,968,225 Jan 11 05:15 PM Nabel Gary J. Chief Innovation Officer Jan 08 '24 Buy 0.93 216,184 200,427 351,442 Jan 10 05:56 PM FROST PHILLIP MD ET AL CEO & Chairman Jan 05 '24 Buy 0.90 1,500,000 1,344,600 203,456,694 Jan 08 08:54 AM Zerhouni Elias A. Vice Chairman and President Jan 05 '24 Buy 0.93 550,300 514,093 20,327,814 Jan 05 05:26 PM HSIAO JANE PH D Vice Chairman & CTO Jan 05 '24 Buy 0.87 150,010 130,899 27,849,880 Jan 08 09:10 AM PFENNIGER RICHARD C JR Director Jan 05 '24 Buy 0.94 25,000 23,429 325,000 Jan 05 12:42 PM PAGANELLI JOHN A Director Jan 05 '24 Buy 0.88 25,000 22,080 384,340 Jan 05 04:00 PM Rubin Steven D Executive VP-Administration Jan 05 '24 Buy 0.87 10,000 8,669 6,187,732 Jan 05 01:39 PM PFENNIGER RICHARD C JR Director Nov 13 '23 Buy 1.30 25,000 32,491 300,000 Nov 14 07:10 AM FROST PHILLIP MD ET AL CEO & Chairman Nov 10 '23 Buy 1.25 500,000 625,462 201,956,694 Nov 13 08:23 AM HSIAO JANE PH D Vice Chairman & CTO Nov 10 '23 Buy 1.27 100,000 126,659 27,699,870 Nov 13 08:21 AM Rubin Steven D Executive VP-Administration Nov 10 '23 Buy 1.30 10,000 13,000 6,177,732 Nov 13 08:21 AM FROST PHILLIP MD ET AL CEO & Chairman Nov 09 '23 Buy 1.28 500,000 641,471 201,456,694 Nov 13 08:23 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 17 '23 Buy 1.76 100,000 175,804 200,956,694 Aug 18 07:10 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 14 '23 Buy 1.75 75,000 131,260 200,856,694 Aug 15 07:05 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 09 '23 Buy 1.82 100,000 181,752 200,781,694 Aug 10 06:59 AM FROST PHILLIP MD ET AL CEO & Chairman Aug 07 '23 Buy 1.84 650,000 1,194,998 200,681,694 Aug 08 07:07 AM Nabel Gary J. Chief Innovation Officer May 05 '23 Buy 1.84 272,637 500,857 19,912,459 May 08 07:03 AM Nabel Gary J. Chief Innovation Officer May 05 '23 Buy 1.81 187,608 340,042 263,079 May 08 07:03 AM
Index - P/E - EPS (ttm) -7.51 Insider Own 37.76% Shs Outstand 25.98M Perf Week 14.94%
Market Cap 288.63M Forward P/E - EPS next Y -1.42 Insider Trans -7.16% Shs Float 16.22M Perf Month 17.12%
Income -175.77M PEG - EPS next Q -0.89 Inst Own 42.36% Short Float 6.59% Perf Quarter 223.98%
Sales 202.57M P/S 1.42 EPS this Y 47.11% Inst Trans -11.90% Short Ratio 5.25 Perf Half Y 265.68%
Book/sh 8.78 P/B 1.26 EPS next Y 48.27% ROA -34.50% Short Interest 1.07M Perf Year 17.48%
Cash/sh 5.00 P/C 2.22 EPS next 5Y - ROE -72.97% 52W Range 1.16 - 12.57 Perf YTD 302.91%
Dividend Est. - P/FCF - EPS past 5Y - ROI -51.15% 52W High -11.85% Beta 2.62
Dividend TTM - Quick Ratio 2.95 Sales past 5Y 5.08% Gross Margin 29.93% 52W Low 855.17% ATR (14) 1.02
Dividend Ex-Date - Current Ratio 3.10 EPS Y/Y TTM 85.48% Oper. Margin -80.80% RSI (14) 58.05 Volatility 11.21% 10.14%
Employees 1000 Debt/Eq 0.53 Sales Y/Y TTM -13.69% Profit Margin -86.77% Recom 2.00 Target Price 11.38
Option/Short Yes / Yes LT Debt/Eq 0.51 EPS Q/Q 96.22% Payout - Rel Volume 0.73 Prev Close 11.17
Sales Surprise 7.11% EPS Surprise 24.87% Sales Q/Q -6.41% Earnings Apr 29 AMC Avg Volume 203.48K Price 11.08
SMA20 9.21% SMA50 22.52% SMA200 118.01% Trades
Volume 148,884 Change -0.81%
Apr-23-24 08:30AM
Apr-04-24 04:05PM
Mar-21-24 09:55AM
Mar-14-24 08:30AM
Feb-26-24 04:05PM
08:33AM
Loading…
Feb-21-24 08:33AM
Feb-20-24 04:26PM
Feb-01-24 04:30PM
Jan-24-24 04:30PM
Jan-08-24 08:55AM
Dec-01-23 08:30AM
Nov-28-23 04:05PM
Nov-20-23 04:05PM
Nov-10-23 09:55AM
Nov-05-23 12:10PM
08:19AM
Loading…
Oct-31-23 08:19AM
(Thomson Reuters StreetEvents) -30.34%
Oct-30-23 06:02PM
04:05PM
Oct-09-23 04:05PM
Sep-22-23 04:05PM
Sep-13-23 01:01PM
Sep-11-23 08:00AM
Sep-06-23 08:00AM
Aug-21-23 07:00AM
Aug-09-23 08:16AM
07:59AM
(Thomson Reuters StreetEvents)
Aug-08-23 08:05PM
04:05PM
Aug-07-23 08:00AM
Jul-19-23 07:05AM
04:05PM
Loading…
Jul-18-23 04:05PM
Jun-28-23 07:00AM
Jun-26-23 04:01PM
Jun-20-23 07:00AM
May-24-23 04:05PM
May-23-23 07:00AM
May-22-23 04:05PM
May-15-23 09:35AM
May-09-23 04:05PM
May-04-23 07:00AM
May-03-23 01:06PM
Apr-28-23 06:39PM
08:10AM
07:04AM
Apr-18-23 04:05PM
12:55PM
Apr-03-23 08:30AM
Mar-22-23 04:36PM
Mar-20-23 09:07PM
08:45AM
Mar-18-23 06:48PM
Mar-16-23 08:45AM
Mar-14-23 04:16PM
Mar-01-23 07:30AM
Feb-28-23 08:30AM
Feb-21-23 04:30PM
Feb-16-23 08:30AM
Jan-31-23 04:15PM
Jan-30-23 08:30AM
Jan-27-23 06:00AM
Jan-26-23 04:53PM
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 18 '24 Sale 10.59 8,559 90,661 66,698 Mar 19 04:15 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 18 '24 Sale 10.59 3,253 34,455 28,927 Mar 19 04:14 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 18 '24 Sale 10.59 2,008 21,269 29,517 Mar 19 04:14 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 16 '24 Option Exercise 0.00 18,750 0 75,257 Mar 19 04:15 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 16 '24 Option Exercise 0.00 7,197 0 32,180 Mar 19 04:14 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 16 '24 Option Exercise 0.00 5,114 0 31,525 Mar 19 04:14 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 12 '24 Sale 9.21 2,618 24,111 56,507 Mar 13 04:24 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 12 '24 Sale 9.21 931 8,574 24,983 Mar 13 04:28 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 12 '24 Sale 9.21 897 8,261 26,411 Mar 13 04:22 PM Feeley Kevin CHIEF FINANCIAL OFFICER Mar 09 '24 Option Exercise 0.00 2,462 0 25,914 Mar 12 05:27 PM Stueland Katherine CHIEF EXECUTIVE OFFICER Mar 09 '24 Option Exercise 0.00 6,547 0 59,125 Mar 12 05:26 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Mar 09 '24 Option Exercise 0.00 2,841 0 27,308 Mar 12 05:25 PM Casdin Capital, LLC Director Mar 05 '24 Buy 8.83 900 7,944 2,703,509 Mar 06 07:32 PM Casdin Capital, LLC Director Mar 04 '24 Buy 8.74 40,000 349,708 2,702,609 Mar 06 07:32 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Jan 22 '24 Sale 3.24 193 625 24,467 Jan 23 04:10 PM Saad Kareem CHIEF TRANSFORMATION OFFICER Jan 19 '24 Option Exercise 0.00 546 0 24,660 Jan 23 04:10 PM Saad Kareem Chief Transformation Officer Jan 03 '24 Sale 2.58 105 271 24,114 Jan 04 05:03 PM Saad Kareem Chief Transformation Officer Jan 01 '24 Option Exercise 0.00 273 0 24,219 Jan 03 04:25 PM Ryan Jason Executive Chairman Dec 31 '23 Option Exercise 0.00 67,780 0 73,614 Jan 03 04:23 PM Stueland Katherine Chief Executive Officer Dec 18 '23 Sale 2.16 11,734 25,338 52,578 Dec 19 09:26 PM Feeley Kevin Chief Financial Officer Dec 18 '23 Sale 2.16 2,948 6,366 23,035 Dec 19 09:24 PM Saad Kareem Chief Transformation Officer Dec 18 '23 Sale 2.16 1,700 3,671 23,946 Dec 19 09:25 PM Stueland Katherine Chief Executive Officer Dec 16 '23 Option Exercise 0.00 18,750 0 64,312 Dec 19 09:26 PM Saad Kareem Chief Transformation Officer Dec 16 '23 Option Exercise 0.00 5,114 0 25,646 Dec 19 09:25 PM Feeley Kevin Chief Financial Officer Dec 16 '23 Option Exercise 0.00 7,197 0 25,983 Dec 19 09:24 PM Stueland Katherine Chief Executive Officer Dec 11 '23 Sale 1.61 3,673 5,915 45,562 Dec 12 04:06 PM Feeley Kevin Chief Financial Officer Dec 11 '23 Sale 1.61 908 1,462 18,786 Dec 12 04:04 PM Saad Kareem Chief Transformation Officer Dec 11 '23 Sale 1.61 850 1,369 20,532 Dec 12 04:05 PM Saad Kareem Chief Transformation Officer Dec 09 '23 Option Exercise 0.00 2,841 0 21,382 Dec 12 04:05 PM Stueland Katherine Chief Executive Officer Dec 09 '23 Option Exercise 0.00 6,546 0 49,235 Dec 12 04:06 PM Feeley Kevin Chief Financial Officer Dec 09 '23 Option Exercise 0.00 2,462 0 19,694 Dec 12 04:04 PM Feeley Kevin Chief Financial Officer Dec 04 '23 Sale 1.77 270 478 17,232 Dec 05 04:45 PM Ryan Jason Executive Chairman Nov 17 '23 Buy 1.54 58,000 89,181 114,742 Nov 20 04:32 PM Ryan Jason Executive Chairman Nov 16 '23 Buy 1.27 56,742 72,187 56,742 Nov 20 04:32 PM Meister Keith A. Director Nov 15 '23 Sale 1.29 883,742 1,140,027 3,011,066 Nov 17 04:18 PM PFENNIGER RICHARD C JR Director Nov 08 '23 Buy 1.49 10,000 14,889 20,918 Nov 08 07:19 PM Saad Kareem Chief Transformation Officer Oct 20 '23 Sale 3.44 164 564 18,541 Oct 23 05:52 PM Ryan Jason Executive Chairman Oct 17 '23 Sale 3.19 42 134 5,834 Oct 18 04:59 PM Saad Kareem Chief Transformation Officer Oct 03 '23 Sale 3.56 85 303 18,159 Oct 03 04:19 PM Stueland Katherine Chief Executive Officer Sep 18 '23 Sale 4.16 10,752 44,749 42,689 Sep 19 06:09 PM Feeley Kevin Chief Financial Officer Sep 18 '23 Sale 4.16 2,742 11,409 16,785 Sep 19 06:08 PM Saad Kareem Chief Transformation Officer Sep 18 '23 Sale 4.16 1,580 6,575 17,971 Sep 19 06:08 PM Feeley Kevin Chief Financial Officer Sep 16 '23 Option Exercise 0.00 7,197 0 19,527 Sep 19 06:08 PM Stueland Katherine Chief Executive Officer Sep 11 '23 Sale 4.62 2,675 12,369 34,691 Sep 12 06:42 PM Feeley Kevin Chief Financial Officer Sep 11 '23 Sale 4.62 904 4,180 12,330 Sep 12 06:40 PM Saad Kareem Chief Transformation Officer Sep 11 '23 Sale 4.62 846 3,912 14,437 Sep 12 06:41 PM Feeley Kevin Chief Financial Officer Sep 09 '23 Option Exercise 0.00 2,462 0 13,234 Sep 12 06:40 PM Feeley Kevin Chief Financial Officer Sep 05 '23 Sale 4.38 269 1,178 10,772 Sep 06 04:56 PM PFENNIGER RICHARD C JR Director Aug 17 '23 Buy 5.10 5,000 25,523 10,918 Aug 18 05:10 PM White Karen Ann Chief People Officer Jul 26 '23 Sale 7.41 61 452 4,761 Jul 27 04:12 PM Saad Kareem Chief Transformation Officer Jul 20 '23 Sale 7.85 163 1,280 12,442 Jul 21 09:58 PM Saad Kareem Chief Transformation Officer Jul 03 '23 Sale 5.99 83 497 12,059 Jul 05 05:16 PM White Karen Ann Chief People Officer Jul 03 '23 Sale 5.99 45 270 4,685 Jul 05 05:18 PM Stueland Katherine Chief Executive Officer Jun 20 '23 Sale 6.37 7,965 50,727 30,819 Jun 21 04:05 PM Feeley Kevin Chief Financial Officer Jun 20 '23 Sale 6.37 2,744 17,473 10,324 Jun 21 04:06 PM White Karen Ann Chief People Officer Jun 20 '23 Sale 6.37 1,549 9,865 4,631 Jun 21 04:05 PM Saad Kareem Chief Transformation Officer Jun 20 '23 Sale 6.37 1,221 7,774 11,869 Jun 21 04:04 PM Feeley Kevin Chief Financial Officer Jun 16 '23 Option Exercise 0.00 7,197 0 13,068 Jun 21 04:06 PM Feeley Kevin Chief Financial Officer Jun 13 '23 Sale 6.49 903 5,860 5,871 Jun 13 05:19 PM Stueland Katherine Chief Executive Officer Jun 12 '23 Sale 6.49 2,674 17,354 20,034 Jun 13 05:23 PM Saad Kareem Chief Transformation Officer Jun 12 '23 Sale 6.49 845 5,484 7,976 Jun 13 05:22 PM White Karen Ann Chief People Officer Jun 12 '23 Sale 6.49 828 5,374 2,770 Jun 13 05:25 PM Feeley Kevin Chief Financial Officer Jun 09 '23 Option Exercise 0.00 2,462 0 6,774 Jun 13 05:19 PM Feeley Kevin Chief Financial Officer Jun 02 '23 Sale 7.00 263 1,841 4,312 Jun 05 04:42 PM PFENNIGER RICHARD C JR Director May 18 '23 Buy 5.90 5,000 29,500 5,918 May 22 04:59 PM Stueland Katherine Chief Executive Officer May 16 '23 Sale 6.50 8,685 56,439 16,162 May 18 07:21 PM Feeley Kevin Chief Financial Officer May 16 '23 Sale 6.50 1,516 9,852 3,856 May 18 07:22 PM Sherman Rachel E. Director May 02 '23 Option Exercise 0.00 45,454 0 58,290 May 04 04:15 PM Casdin Eli Director May 02 '23 Option Exercise 0.00 45,454 0 58,290 May 04 04:04 PM Leproust Emily M. Director May 02 '23 Option Exercise 0.00 45,454 0 83,290 May 04 04:07 PM RUCH JOSHUA Director May 02 '23 Option Exercise 0.00 45,454 0 62,568 May 04 04:14 PM PFENNIGER RICHARD C JR Director May 02 '23 Option Exercise 0.00 30,303 0 30,303 May 04 04:11 PM Meister Keith A. Director May 02 '23 Option Exercise 0.00 45,454 0 45,454 May 04 04:09 PM Feeley Kevin Chief Financial Officer Apr 29 '23 Option Exercise 0.00 99,432 0 177,292 May 02 08:32 PM
Index - P/E - EPS (ttm) -4.60 Insider Own 49.03% Shs Outstand 13.55M Perf Week 11.74%
Market Cap 40.12M Forward P/E 32.78 EPS next Y 0.09 Insider Trans 8.42% Shs Float 6.93M Perf Month -2.47%
Income -63.22M PEG - EPS next Q -0.15 Inst Own 24.57% Short Float 1.38% Perf Quarter -25.16%
Sales 298.40M P/S 0.13 EPS this Y 83.33% Inst Trans - Short Ratio 3.59 Perf Half Y 9.26%
Book/sh 2.54 P/B 1.16 EPS next Y 200.00% ROA -42.74% Short Interest 0.10M Perf Year -33.12%
Cash/sh 1.16 P/C 2.54 EPS next 5Y 40.00% ROE -98.50% 52W Range 2.31 - 4.78 Perf YTD -26.62%
Dividend Est. - P/FCF 5.29 EPS past 5Y - ROI -102.64% 52W High -38.23% Beta 2.45
Dividend TTM - Quick Ratio 1.59 Sales past 5Y 4.23% Gross Margin 22.67% 52W Low 27.73% ATR (14) 0.26
Dividend Ex-Date - Current Ratio 1.59 EPS Y/Y TTM 49.25% Oper. Margin -2.63% RSI (14) 54.72 Volatility 6.80% 9.01%
Employees 277 Debt/Eq 1.00 Sales Y/Y TTM -17.37% Profit Margin -21.19% Recom 3.00 Target Price 12.00
Option/Short No / Yes LT Debt/Eq 0.79 EPS Q/Q 97.23% Payout - Rel Volume 1.85 Prev Close 2.78
Sales Surprise -1.78% EPS Surprise 100.00% Sales Q/Q -14.06% Earnings Apr 02 AMC Avg Volume 26.66K Price 2.95
SMA20 5.08% SMA50 -0.58% SMA200 -12.18% Trades
Volume 49,429 Change 6.12%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-22 Upgrade Barrington Research
Mkt Perform → Outperform
$2.50
Mar-17-21 Downgrade Barrington Research
Outperform → Mkt Perform
Nov-02-20 Upgrade Barrington Research
Mkt Perform → Outperform
$4.50
Aug-26-20 Initiated Canaccord Genuity
Buy
$5
Nov-12-19 Downgrade Barrington Research
Outperform → Mkt Perform
May-09-19 Upgrade ROTH Capital
Neutral → Buy
$5.50 → $8.50
Apr-10-24 08:00AM
Apr-03-24 09:00AM
06:44AM
(Thomson Reuters StreetEvents)
Apr-02-24 05:32PM
Apr-01-24 10:48PM
09:00AM
Loading…
Mar-21-24 09:00AM
Feb-29-24 02:25PM
12:22PM
Feb-27-24 09:00AM
Jan-25-24 08:30AM
Nov-15-23 09:55AM
(Thomson Reuters StreetEvents) -16.50%
Nov-14-23 05:11PM
04:54PM
(Associated Press Finance)
04:15PM
Nov-03-23 03:00PM
08:30AM
Loading…
Aug-22-23 08:30AM
Aug-15-23 12:04PM
06:05AM
(Thomson Reuters StreetEvents)
Aug-14-23 04:30PM
Aug-09-23 09:09PM
Aug-08-23 08:30AM
Aug-02-23 08:30AM
Aug-01-23 03:30PM
Jul-27-23 08:30AM
Jul-10-23 10:14AM
Jun-13-23 08:42AM
May-17-23 06:15AM
May-16-23 08:01AM
(Thomson Reuters StreetEvents) -20.19%
May-15-23 04:15PM
May-12-23 02:10PM
09:40AM
Loading…
May-11-23 09:40AM
May-02-23 05:50PM
08:30AM
May-01-23 09:00AM
Apr-26-23 05:50PM
Apr-20-23 05:50PM
Apr-18-23 10:02AM
09:00AM
Apr-07-23 09:35AM
Apr-06-23 08:30AM
Apr-05-23 09:40AM
Mar-20-23 09:40AM
05:33AM
Mar-18-23 03:12AM
Mar-17-23 06:16AM
Mar-16-23 05:53AM
(Thomson Reuters StreetEvents) -32.63%
Mar-15-23 04:15PM
Feb-27-23 09:00AM
Feb-08-23 09:40AM
Jan-25-23 05:50AM
Jan-20-23 09:40AM
Jan-15-23 03:10PM
Dec-22-22 07:38AM
Nov-07-22 04:01PM
Oct-26-22 08:30AM
Oct-19-22 07:53AM
Oct-17-22 08:30AM
Oct-11-22 08:30AM
Oct-05-22 08:30AM
Sep-14-22 06:30AM
Sep-13-22 08:30AM
Aug-18-22 06:16AM
Aug-09-22 08:00PM
05:55PM
04:30PM
(Thomson Reuters StreetEvents)
04:01PM
Aug-08-22 11:30AM
Aug-04-22 05:51PM
Jul-22-22 08:50AM
Jul-15-22 06:10AM
May-25-22 09:00AM
May-13-22 04:06PM
May-12-22 06:44AM
May-09-22 09:00PM
06:25PM
06:04PM
May-02-22 03:00PM
Apr-28-22 12:00PM
09:00AM
Apr-19-22 09:00AM
Mar-23-22 09:00AM
Mar-22-22 09:00AM
Mar-21-22 09:30AM
Mar-08-22 08:30PM
05:45PM
04:20PM
Mar-02-22 08:30AM
Mar-01-22 08:30AM
Jan-03-22 05:24AM
Nov-15-21 08:30AM
Nov-05-21 04:01PM
Nov-04-21 08:56PM
04:15PM
Oct-29-21 09:00AM
Oct-28-21 04:30PM
Oct-08-21 09:23AM
Oct-05-21 09:00AM
08:30AM
Sep-07-21 09:00AM
Aug-10-21 07:01AM
Fluent, Inc. engages in the provision of digital marketing services. It operates through the Fluent and All Other segments. The Fluent segment includes delivering data and performance-based marketing executions. The All Other segment represents the operation results of AdParlor, LLC, a digital advertising solution for social media buying. The company was founded by Ryan Schulke and Matthew Conlin in 2001 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schulke Ryan Chief Strategy Officer Mar 14 '24 Buy 0.53 21,000 11,128 600,159 Mar 14 05:57 PM Schulke Ryan Chief Strategy Officer Mar 13 '24 Buy 0.53 10,000 5,299 579,159 Mar 14 05:57 PM Schulke Ryan Chief Strategy Officer Mar 12 '24 Buy 0.59 20,000 11,858 569,159 Mar 12 06:17 PM Perfit Ryan MacNab Interim CFO Mar 11 '24 Buy 0.58 10,000 5,787 45,596 Mar 12 06:26 PM Schulke Ryan Chief Strategy Officer Mar 08 '24 Buy 0.62 10,000 6,187 549,159 Mar 11 09:43 PM Perfit Ryan MacNab Interim CFO Mar 08 '24 Buy 0.57 596 340 35,596 Mar 12 06:26 PM Schulke Ryan Chief Strategy Officer Mar 07 '24 Buy 0.59 10,000 5,900 539,159 Mar 07 05:43 PM Schulke Ryan Chief Strategy Officer Mar 06 '24 Buy 0.52 10,000 5,201 529,159 Mar 06 06:25 PM Schulke Ryan Chief Strategy Officer Mar 05 '24 Buy 0.53 10,000 5,336 519,159 Mar 06 06:25 PM Schulke Ryan Chief Strategy Officer Mar 04 '24 Buy 0.60 10,000 5,973 509,159 Mar 06 06:25 PM Perfit Ryan MacNab Interim CFO Mar 04 '24 Buy 0.59 10,000 5,900 35,000 Mar 06 06:25 PM Schulke Ryan Chief Strategy Officer Dec 14 '23 Buy 0.58 12,000 6,922 499,159 Dec 18 05:58 PM Conlin Matthew Chief Customer Officer Dec 14 '23 Buy 0.58 5,000 2,880 211,970 Dec 18 05:57 PM Schulke Ryan Chief Strategy Officer Dec 13 '23 Buy 0.53 10,659 5,611 487,159 Dec 14 10:23 AM Schulke Ryan Chief Strategy Officer Dec 12 '23 Buy 0.51 12,000 6,107 476,500 Dec 14 10:23 AM Conlin Matthew Chief Customer Officer Dec 12 '23 Buy 0.51 5,000 2,544 206,970 Dec 14 10:28 AM Schulke Ryan Chief Strategy Officer Dec 11 '23 Buy 0.51 12,000 6,077 464,500 Dec 12 09:54 AM Schulke Ryan Chief Strategy Officer Dec 08 '23 Buy 0.51 12,000 6,065 452,500 Dec 12 09:54 AM Conlin Matthew Chief Customer Officer Dec 08 '23 Buy 0.50 4,500 2,272 201,970 Dec 12 09:57 AM Schulke Ryan Chief Strategy Officer Dec 07 '23 Buy 0.50 12,000 6,044 440,500 Dec 08 02:50 PM Schulke Ryan Chief Strategy Officer Dec 06 '23 Buy 0.50 12,000 6,030 428,500 Dec 08 02:50 PM Schulke Ryan Chief Strategy Officer Dec 05 '23 Buy 0.51 12,000 6,074 416,500 Dec 05 06:13 PM Perfit Ryan MacNab Interim CFO Dec 05 '23 Buy 0.50 10,000 5,000 25,000 Dec 07 08:46 AM Schulke Ryan Chief Strategy Officer Dec 04 '23 Buy 0.52 12,000 6,208 404,500 Dec 05 06:13 PM Conlin Matthew Chief Customer Officer Dec 04 '23 Buy 0.52 5,000 2,586 197,470 Dec 07 08:44 AM Schulke Ryan Chief Strategy Officer Dec 01 '23 Buy 0.52 12,000 6,206 392,500 Dec 05 06:13 PM Schulke Ryan Chief Strategy Officer Nov 30 '23 Buy 0.52 12,000 6,246 380,500 Nov 30 09:01 PM Schulke Ryan Chief Strategy Officer Nov 29 '23 Buy 0.50 12,000 6,052 368,500 Nov 30 09:01 PM Conlin Matthew Chief Customer Officer Nov 29 '23 Buy 0.51 3,700 1,869 192,470 Nov 30 08:59 PM Schulke Ryan Chief Strategy Officer Nov 28 '23 Buy 0.51 12,000 6,108 356,500 Nov 30 09:01 PM Conlin Matthew Chief Customer Officer Nov 28 '23 Buy 0.51 3,700 1,886 188,770 Nov 30 08:59 PM Schulke Ryan Chief Strategy Officer Nov 27 '23 Buy 0.51 12,000 6,104 344,500 Nov 27 06:32 PM Conlin Matthew Chief Customer Officer Nov 27 '23 Buy 0.51 3,700 1,885 185,070 Nov 27 06:25 PM Schulke Ryan Chief Strategy Officer Nov 24 '23 Buy 0.51 12,000 6,116 332,500 Nov 27 06:32 PM Conlin Matthew Chief Customer Officer Nov 24 '23 Buy 0.51 3,800 1,937 181,370 Nov 27 06:25 PM Schulke Ryan Chief Strategy Officer Nov 22 '23 Buy 0.51 12,000 6,139 320,500 Nov 27 06:32 PM Conlin Matthew Chief Customer Officer Nov 22 '23 Buy 0.51 5,000 2,560 177,570 Nov 27 06:25 PM Schulke Ryan Chief Strategy Officer Nov 21 '23 Buy 0.53 12,000 6,358 308,500 Nov 21 09:23 PM Conlin Matthew Chief Customer Officer Nov 21 '23 Buy 0.53 5,000 2,638 172,570 Nov 21 09:28 PM Schulke Ryan Chief Strategy Officer Nov 20 '23 Buy 0.54 12,000 6,460 296,500 Nov 21 09:23 PM Conlin Matthew Chief Customer Officer Nov 20 '23 Buy 0.52 10,000 5,200 167,570 Nov 21 09:28 PM Schulke Ryan Chief Strategy Officer Nov 17 '23 Buy 0.52 12,000 6,247 284,500 Nov 21 09:23 PM Conlin Matthew Chief Customer Officer Nov 17 '23 Buy 0.52 10,000 5,200 157,570 Nov 21 09:28 PM FROST PHILLIP MD ET AL 10% Owner Sep 19 '23 Buy 0.46 100,000 46,000 18,834,874 Sep 21 04:44 PM Schulke Ryan Chief Strategy Officer May 19 '23 Buy 0.70 40,000 27,812 272,500 May 23 01:24 PM Conlin Matthew Chief Customer Officer May 19 '23 Buy 0.68 40,000 27,168 147,570 May 30 07:40 PM Perfit Ryan MacNab Interim CFO May 18 '23 Buy 0.67 15,000 9,999 15,000 May 26 02:34 PM Patrick Donald Huntley Chief Executive Officer May 18 '23 Buy 0.65 4,800 3,134 1,600,911 May 22 07:27 PM
Index - P/E - EPS (ttm) -0.32 Insider Own 1.95% Shs Outstand 271.99M Perf Week -0.40%
Market Cap 67.73M Forward P/E - EPS next Y -0.14 Insider Trans 0.00% Shs Float 266.67M Perf Month 6.41%
Income -78.43M PEG - EPS next Q -0.05 Inst Own 9.77% Short Float 6.19% Perf Quarter -7.78%
Sales 8.58M P/S 7.89 EPS this Y 38.33% Inst Trans -7.21% Short Ratio 10.20 Perf Half Y 14.33%
Book/sh 0.13 P/B 1.97 EPS next Y 21.62% ROA -88.23% Short Interest 16.51M Perf Year -61.65%
Cash/sh 0.08 P/C 3.21 EPS next 5Y - ROE -117.89% 52W Range 0.20 - 0.70 Perf YTD -21.92%
Dividend Est. - P/FCF - EPS past 5Y 39.50% ROI -206.08% 52W High -64.38% Beta 1.44
Dividend TTM - Quick Ratio 2.31 Sales past 5Y 7.80% Gross Margin -58.66% 52W Low 22.06% ATR (14) 0.02
Dividend Ex-Date - Current Ratio 2.88 EPS Y/Y TTM 1.03% Oper. Margin -910.92% RSI (14) 44.19 Volatility 3.99% 5.68%
Employees 209 Debt/Eq 0.17 Sales Y/Y TTM 21.02% Profit Margin -914.46% Recom 3.00 Target Price 0.35
Option/Short Yes / Yes LT Debt/Eq 0.14 EPS Q/Q 13.64% Payout - Rel Volume 0.37 Prev Close 0.24
Sales Surprise -0.35% EPS Surprise -7.69% Sales Q/Q 120.41% Earnings Mar 21 AMC Avg Volume 1.62M Price 0.25
SMA20 -2.83% SMA50 -9.37% SMA200 -15.46% Trades
Volume 606,139 Change 3.32%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-16-23 Downgrade Cantor Fitzgerald
Overweight → Neutral
Sep-08-22 Initiated Cantor Fitzgerald
Overweight
$1.50
May-26-21 Initiated H.C. Wainwright
Buy
$4
Apr-03-24 08:45AM
Mar-21-24 04:05PM
Mar-15-24 06:55AM
Feb-28-24 06:55AM
Feb-27-24 06:55AM
09:35AM
Loading…
Feb-06-24 09:35AM
Jan-16-24 06:55AM
Jan-08-24 06:45AM
Jan-04-24 04:15PM
Jan-03-24 06:55AM
Dec-20-23 06:55AM
Dec-04-23 06:55AM
Nov-14-23 04:05PM
06:55AM
Nov-13-23 04:15PM
06:55AM
Loading…
Nov-07-23 06:55AM
Nov-06-23 06:55AM
Sep-07-23 06:55AM
Sep-05-23 06:55AM
Aug-23-23 06:55AM
Aug-17-23 08:30AM
Aug-10-23 04:05PM
Aug-01-23 06:55AM
Jul-27-23 09:01AM
Jul-14-23 06:55AM
Jun-01-23 09:28AM
May-11-23 04:05PM
Apr-27-23 06:55AM
Apr-25-23 06:55AM
Apr-19-23 06:55AM
06:55AM
Loading…
Mar-20-23 06:55AM
Mar-06-23 06:55AM
Mar-02-23 04:05PM
Feb-27-23 06:55AM
Feb-21-23 11:14AM
Feb-16-23 06:55AM
Feb-14-23 06:55AM
Feb-09-23 06:55AM
Jan-30-23 06:55AM
Jan-23-23 06:55AM
Jan-09-23 06:55AM
Jan-05-23 06:55AM
Jan-03-23 06:55AM
Dec-29-22 06:55AM
Dec-19-22 06:55AM
Dec-08-22 06:55AM
Nov-28-22 06:55AM
Nov-10-22 04:05PM
Nov-08-22 06:55AM
Oct-31-22 06:55AM
Oct-18-22 06:55AM
Sep-28-22 06:55AM
Sep-09-22 06:55AM
Aug-31-22 06:55AM
Aug-30-22 06:55AM
Aug-08-22 04:05PM
Aug-04-22 06:55AM
Jul-26-22 06:50AM
Jul-07-22 06:50AM
Jun-28-22 08:30AM
06:50AM
May-24-22 08:04AM
(American City Business Journals) -8.62%
May-11-22 06:55AM
May-04-22 04:05PM
Apr-27-22 06:55AM
Apr-20-22 08:30AM
Feb-28-22 04:05PM
Feb-22-22 06:55AM
Jan-26-22 01:10PM
Jan-10-22 06:50AM
Dec-29-21 06:55AM
Nov-29-21 06:55AM
Nov-15-21 06:55AM
Nov-03-21 04:05PM
Nov-01-21 06:55AM
Oct-20-21 06:55AM
Oct-06-21 06:55AM
Oct-04-21 04:15PM
Sep-29-21 08:00AM
Sep-27-21 06:55AM
Sep-08-21 06:55AM
Sep-01-21 08:00AM
Aug-05-21 04:05PM
Jul-28-21 09:00AM
Jul-26-21 06:55AM
Jul-22-21 06:55AM
Jul-14-21 06:55AM
Jul-01-21 06:55AM
Jun-29-21 12:15PM
Jun-28-21 08:50AM
Jun-08-21 06:55AM
Jun-03-21 03:03PM
May-28-21 08:00AM
May-20-21 06:55AM
May-17-21 09:00AM
May-13-21 08:27AM
May-12-21 09:00AM
May-11-21 04:05PM
02:30PM
May-10-21 07:45AM
Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fernando Anthony C. J. President and CEO Apr 21 '24 Option Exercise 0.00 271,739 0 2,318,332 Apr 23 05:46 PM Shameze Rampertab EVP, Chief Financial Officer Apr 21 '24 Option Exercise 0.00 81,521 0 459,926 Apr 23 05:47 PM Fernando Anthony C. J. President and CEO Feb 04 '24 Option Exercise 0.00 1,042,772 0 2,531,165 Feb 06 07:00 PM Shameze Rampertab EVP, Chief Financial Officer Feb 04 '24 Option Exercise 0.00 280,909 0 528,772 Feb 06 07:01 PM Starling William N JR Director Dec 14 '23 Buy 0.28 18,134 5,078 39,134 Dec 18 06:26 PM Starling William N JR Director Dec 14 '23 Sale 0.28 18,134 5,078 0 Dec 18 06:26 PM Shameze Rampertab EVP, Chief Financial Officer Jul 01 '23 Option Exercise 0.00 16,666 0 254,838 Jul 05 05:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
